Scholarlink

<p>Direct-acting antivirals (DAAs) achieve high sustained virologic response (SVR) rates in patients with hepatitis C virus (HCV) infection. However, the long-term prognosis and cause-specific mortality post-SVR remain unclear. This study analyzed 1753 HCV-infected patients without a history of hepatocellular carcinoma treatment who achieved SVR with DAAs and did not develop cancer. Liver disease-related (LDR) and non-LDR mortalities were assessed using age- and sex-adjusted standardized mortality ratios (SMRs) compared with the general population. During a mean follow-up of 59.2&#xa0;months, 122 patients died. The SMR for all-cause mortality was 1.050 (<i>p</i> = 0.588). The SMRs for LDR and non-LDR mortalities were 7.819 (<i>p</i> &lt; 0.001) and 0.566 (<i>p</i> &lt; 0.001), respectively. The SMR for extrahepatic malignancy-related mortality was significantly lower at 0.593 (<i>p</i> = 0.013), whereas cardiovascular disease (CVD)-related mortality did not differ significantly at 0.884 (<i>p</i> = 0.554). These findings were consistent regardless of age, sex, liver cirrhosis presence, diabetes, or chronic kidney disease. Overall mortality after SVR in patients with HCV was comparable with that of the general population. Nevertheless, LDR mortality remained significantly elevated, whereas non-LDR and extrahepatic malignancy-related mortalities were significantly reduced. These results underscore the importance of continued liver disease surveillance post-SVR, while CVD management should parallel that of the general population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cause-specific mortality following sustained virologic response in hepatitis C patients treated with direct-acting antivirals: a standardized mortality ratio analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月27日

查看全文
  • Seiichi Mawatari,
  • Shiroh Tanoue,
  • Kotaro Kumagai,
  • Kohei Oda,
  • Ai Toyodome,
  • Haruka Sakae,
  • Kunio Fujisaki,
  • Yukiko Inada,
  • Hirofumi Uto,
  • Akiko Saisyoji,
  • Yasunari Hiramine,
  • Kazuaki Tabu,
  • Sho Ijuin,
  • Takeshi Hori,
  • Tsutomu Tamai,
  • Akihiro Moriuchi,
  • Shuji Kanmura,
  • Akio Ido

摘要

Direct-acting antivirals (DAAs) achieve high sustained virologic response (SVR) rates in patients with hepatitis C virus (HCV) infection. However, the long-term prognosis and cause-specific mortality post-SVR remain unclear. This study analyzed 1753 HCV-infected patients without a history of hepatocellular carcinoma treatment who achieved SVR with DAAs and did not develop cancer. Liver disease-related (LDR) and non-LDR mortalities were assessed using age- and sex-adjusted standardized mortality ratios (SMRs) compared with the general population. During a mean follow-up of 59.2 months, 122 patients died. The SMR for all-cause mortality was 1.050 (p = 0.588). The SMRs for LDR and non-LDR mortalities were 7.819 (p < 0.001) and 0.566 (p < 0.001), respectively. The SMR for extrahepatic malignancy-related mortality was significantly lower at 0.593 (p = 0.013), whereas cardiovascular disease (CVD)-related mortality did not differ significantly at 0.884 (p = 0.554). These findings were consistent regardless of age, sex, liver cirrhosis presence, diabetes, or chronic kidney disease. Overall mortality after SVR in patients with HCV was comparable with that of the general population. Nevertheless, LDR mortality remained significantly elevated, whereas non-LDR and extrahepatic malignancy-related mortalities were significantly reduced. These results underscore the importance of continued liver disease surveillance post-SVR, while CVD management should parallel that of the general population.